The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations
- PMID: 109198
The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations
Abstract
An analysis of 231 patients with stages I, II, and asymptomatic III ovarian cancer, studied in a prospective randomized-stratified trial, is presented. None of the stage IA patients with well-differentiated tumors have had disease relapses; one fourth of the patients with poorly differentiated tumors have had disease relapses throughout the peritoneal cavity. There is therefore little justification for pelvic radiation alone as postoperative therapy for stage IA ovarian carcinoma. For stage IB, II, and asymptomatic III presentations, patients with an incomplete initial pelvic operation had poor survival characteristics with all tested therapies. For patients in whom the operation was completed, abdominopelvic radiation was superior to pelvic radiation alone or followed by chlorambucil, with respect to long-term survival and control of abdominal disease. The effectiveness of abdominopelvic radiation was independent of stage or histology. The value of abdominopelvic radiation was most strikingly seen in patients with no visible residual tumor.
Similar articles
-
Gynecological malignancies.Cancer Chemother Biol Response Modif. 1996;16:564-91. Cancer Chemother Biol Response Modif. 1996. PMID: 8639401 Review.
-
Prognostic factors in patients with stage I epithelial ovarian cancer.Obstet Gynecol. 1990 Feb;75(2):263-73. Obstet Gynecol. 1990. PMID: 2300355
-
Radiation therapy for patients with ovarian cancer.Strahlentherapie. 1983 Mar;159(3):131-7. Strahlentherapie. 1983. PMID: 6340251 Clinical Trial.
-
Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.Gynecol Oncol. 2005 Feb;96(2):307-13. doi: 10.1016/j.ygyno.2004.08.040. Gynecol Oncol. 2005. PMID: 15661213 Clinical Trial.
-
Advances in the management of epithelial ovarian cancer.J Reprod Med. 2005 Jun;50(6):426-38. J Reprod Med. 2005. PMID: 16050567 Review.
Cited by
-
18F-FDG-PET/CT-guided intensity-modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study.Oncol Lett. 2019 Jan;17(1):149-158. doi: 10.3892/ol.2018.9601. Epub 2018 Oct 19. Oncol Lett. 2019. PMID: 30655750 Free PMC article.
-
Whole abdominal radiotherapy in ovarian cancer.Rep Pract Oncol Radiother. 2010 Mar 23;15(2):27-30. doi: 10.1016/j.rpor.2010.02.004. eCollection 2010. Rep Pract Oncol Radiother. 2010. PMID: 24376920 Free PMC article.
-
Update in cancer chemotherapy: genitourinary tract cancer, Part 5: Ovarian cancer.J Natl Med Assoc. 1988 May;80(5):565-76. J Natl Med Assoc. 1988. PMID: 3047411 Free PMC article. Review.
-
Recent progress in the treatment of epithelial ovarian malignancy.West J Med. 1982 Oct;137(4):273-7. West J Med. 1982. PMID: 7179943 Free PMC article.
-
Cancer of the ovary.Br Med J. 1979 Oct 13;2(6195):935. doi: 10.1136/bmj.2.6195.935-b. Br Med J. 1979. PMID: 519242 Free PMC article. No abstract available.